- Trials with a EudraCT protocol (130)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
130 result(s) found for: Chromosome 15.
Displaying page 4 of 7.
EudraCT Number: 2017-001691-39 | Sponsor Protocol Number: UKM17_0023 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:University Hospital Münster | |||||||||||||
Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |||||||||||||
Medical condition: Lymphoblastic lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002260-33 | Sponsor Protocol Number: CA180-226 | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Bristol-Myers Squibb Internaltional Corporation | |||||||||||||
Full Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised... | |||||||||||||
Medical condition: Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006048-15 | Sponsor Protocol Number: ALL2820 | Start Date*: 2021-05-03 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherap... | ||||||||||||||||||
Medical condition: Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002821-32 | Sponsor Protocol Number: FENDEEP | Start Date*: 2021-12-09 | |||||||||||
Sponsor Name:Neurologia Aplicada, SLP | |||||||||||||
Full Title: The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. | |||||||||||||
Medical condition: Five different types of developmental and epileptic encephalopathies (DEEs): SYNGAP1 and STXBP1 encephalopathies, inv-dup(15) encephalopathy, multifocal or bilateral Malformations of Cortical Devel... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004699-16 | Sponsor Protocol Number: KRT-232-117 | Start Date*: 2021-03-15 | |||||||||||||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukem... | |||||||||||||||||||||||
Medical condition: Phase 1b and Phase 2 Arms A and B: Adults with tumor protein 53 wild type (TP53wt) Philadelphia chromosome positive (Ph+) CML in chronic phase who are refractory or intolerant to ≥ 2 prior TKIs and... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005047-26 | Sponsor Protocol Number: CAMN107A2302 | Start Date*: 2007-10-15 |
Sponsor Name:Novartis Pharma Services | ||
Full Title: A phase III multi-center, open-label, randomized study of the efficacy of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in ... | ||
Medical condition: Nilotinib will be evaluated in patients having showed a suboptimal cytogenetic response to imatinib | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Completed) DE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001286-20 | Sponsor Protocol Number: CABL001I12201 | Start Date*: 2021-07-29 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||||||||||||
Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP... | |||||||||||||||||||||||
Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003667-11 | Sponsor Protocol Number: M15-550 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000042-37 | Sponsor Protocol Number: GHNOO-1658 | Start Date*: 2005-07-11 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | |||||||||||||
Medical condition: Noonan syndrome associated short stature | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003075-11 | Sponsor Protocol Number: 9HB01EXT | Start Date*: 2011-12-05 | |||||||||||
Sponsor Name:Biogen Idec Research Ltd | |||||||||||||
Full Title: An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant, Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes i... | |||||||||||||
Medical condition: The medical condition to be investigated is Hemophilia B, or Christmas disease. Hemophilia B is a deficiency in the clotting FIX and is a recessively inherited coagulation disorder due to an X-chro... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed) IE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004535-30 | Sponsor Protocol Number: MK-0457 | Start Date*: 2007-03-22 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: CML and Ph+ALL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Completed) DE (Prematurely Ended) FR (Completed) NL (Completed) DK (Prematurely Ended) GB (Completed) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001850-80 | Sponsor Protocol Number: NLG-MCL8 | Start Date*: 2021-04-07 |
Sponsor Name:Skåne University Hospital | ||
Full Title: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma | ||
Medical condition: Mantle Cell Lymphoma (MCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000600-29 | Sponsor Protocol Number: UX023-CL301 | Start Date*: 2016-09-15 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceuticals Inc | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, defective bone mineralisation, and impaired growth plate or endochondral ossification caused by inactivating mutations in t... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) IE (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003392-10 | Sponsor Protocol Number: CMEK162Y2201 | Start Date*: 2012-01-23 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. | ||||||||||||||||||
Medical condition: Noonan syndrome hypertrophic cardiomyopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005506-40 | Sponsor Protocol Number: CLDE225B2203 | Start Date*: 2009-08-06 |
Sponsor Name:Novartis Pharma | ||
Full Title: A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study, to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of... | ||
Medical condition: Gorlin syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001380-61 | Sponsor Protocol Number: CSTI5710102E2 | Start Date*: 2005-04-15 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast c... | |||||||||||||
Medical condition: Ph+ CML in myeloid blast crisis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002221-19 | Sponsor Protocol Number: 2015_29 | Start Date*: 2015-10-20 | |||||||||||
Sponsor Name:CHRU of Lille | |||||||||||||
Full Title: A Multicenter Open label Phase II study of Daratumumab in combination with dexamethasone in Multiple Myeloma resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide – an IFM 2014-04... | |||||||||||||
Medical condition: Multiple Myeloma resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001594-24 | Sponsor Protocol Number: CABL001E2201 | Start Date*: 2018-10-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004540-29 | Sponsor Protocol Number: Pona-CELL | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Ústav hematologie a krevní transfuze | |||||||||||||
Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia | |||||||||||||
Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003069-39 | Sponsor Protocol Number: VARIANT | Start Date*: 2023-06-01 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Venetoclax after TKI to target persisting stem cells in CML | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
